Cullinan Therapeutics (CGEM) said Wednesday that the European Medicines Agency has approved its application to conduct a phase 1 clinical trial for CLN-978 to potentially treat rheumatoid arthritis.
The biopharmaceutical company said the open-label trial will be initiated in Q2 to assess the safety, pharmacokinetics, pharmacodynamics, and effects of CLN-978 in patients with active, difficult-to-treat rheumatoid arthritis.
Cullinan said the study will be held at FAU Erlangen-Nuremberg in Germany and Universita Cattolica del Sacro Cuore in Rome, the company added.
Price: 7.70, Change: -0.10, Percent Change: -1.28
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.